Aromasin and Hypertonic bladder - a phase IV clinical study of FDA data

Summary:

Hypertonic bladder is reported as a side effect among people who take Aromasin (exemestane), especially for people who are female, 60+ old, also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hypertonic bladder when taking Aromasin. It is created by eHealthMe based on reports of 12,620 people who have side effects when taking Aromasin from the FDA, and is updated regularly.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,863 Aromasin users. Check the latest studies of Aromasin.

What is Hypertonic bladder?

Hypertonic bladder (bladder-storage function that causes a sudden urge to urinate) is found to be associated with 597 drugs and 519 conditions by eHealthMe. Check the latest studies of Hypertonic bladder.



On Apr, 10, 2026

12,620 people reported to have side effects when taking Aromasin.
Among them, 35 people (0.28%) have Hypertonic bladder.

Could Aromasin cause Hypertonic bladder?

Among these 35 people:

What is the gender of people who have Hypertonic bladder when taking Aromasin? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Hypertonic bladder when taking Aromasin? *

  • 0-1: 0.0 %
  • 2-9: 3.33 %
  • 10-19: 3.33 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 3.33 %
  • 50-59: 0.0 %
  • 60+: 90.0 %

What are other drugs people take besides Aromasin? *

  1. Aredia: 30 people, 85.71%
  2. Zometa: 30 people, 85.71%
  3. Femara: 25 people, 71.43%
  4. Paxil: 22 people, 62.86%
  5. Proventil: 19 people, 54.29%
  6. Methotrexate: 19 people, 54.29%
  7. Cytoxan: 19 people, 54.29%
  8. Megace: 18 people, 51.43%
  9. Klonopin: 17 people, 48.57%
  10. Atenolol: 16 people, 45.71%

What are other side effects people have besides Hypertonic bladder? *

  1. Osteonecrosis Of Jaw (death of bone of jaw): 30 people, 85.71%
  2. Pain: 30 people, 85.71%
  3. Stress And Anxiety: 30 people, 85.71%
  4. Joint Pain: 29 people, 82.86%
  5. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 28 people, 80.00%
  6. Dyspnea (difficult or laboured breathing): 28 people, 80.00%
  7. Kyphosis (a condition of over-curvature of the thoracic vertebrae (upper back)): 27 people, 77.14%
  8. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 26 people, 74.29%
  9. Gait Disturbance: 26 people, 74.29%
  10. Weakness: 26 people, 74.29%

What are the existing conditions these people have? *

  1. Metastases To Bone (cancer spreads to bone): 8 people, 22.86%
  2. Stress And Anxiety: 7 people, 20.00%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 8.57%
  4. Depression: 3 people, 8.57%
  5. Bone Pain: 3 people, 8.57%
  6. Osteoporosis (bones weak and more likely to break): 2 people, 5.71%
  7. Multiple Myeloma (cancer of the plasma cells): 2 people, 5.71%
  8. High Blood Cholesterol: 2 people, 5.71%
  9. Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 5.71%
  10. Bone Loss: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Aromasin and have Hypertonic bladder?

- Check whether Hypertonic bladder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aromasin:

Hypertonic bladder treatments and more:

How severe was Hypertonic bladder and when was it recovered:

Expand to all the drugs that have ingredients of exemestane:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypertonic bladder:

Browse all the conditions that are associated with Hypertonic bladder:


How the study uses the data?

The study uses data from the FDA. It is based on exemestane (the active ingredients of Aromasin) and Aromasin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: